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The disease natural history of colorectal neoplasm regarding two opposing theories, adenoma–carcinoma sequence and de novo
carcinoma theory, is controversial and rarely quantified. The aims of this study are therefore to estimate the dwelling times of
adenoma–carcinoma sequence by adenoma size and histological type, taking de novo carcinoma into account. The efficacy of
polypectomy was therefore estimated making allowance for two pathways. A case–cohort design, underpinning a cohort with 13908
subjects (including 10496 normal subjects, 2652 polyps, 760 colorectal cancers) who underwent the first examination of
colonoscopy between 1979 and 1998, was devised to estimate parameters associated with two opposing theories by randomly
selecting 305 normal subjects, 300 patients with polyps, and 116 colorectal cancers from the cohort. All the 2652 polyps were linked
to national cancer registry to ascertain 25 invasive carcinomas after polypectomy. For the five-state model associated with adenoma
size, dwelling times of small (0.6–1cm) and large adenoma (41cm) are 7.75 and 5.27 years for the model without considering de
novo, and 17.48 and 15.90 years for the model taking de novo carcinoma into account. Similar findings are observed for the model
associated with histological type. The estimated proportions of de novo carcinoma are 31.87% from the model by adenoma size and
27.81% from the model by histological type. Compared to size less than 5mm, patients with adenoma size between 6 and 10mm
and patients with adenoma size larger than 1cm have 2.17-fold (0.67–10.74) and 4.25-fold (1.23–14.70), respectively, for the risk of
malignant transformation. There are similar findings for the model by histological type. The estimates of overall efficacy of
colonoscopy in reducing CRC is 73% for the model allowing for de novo carcinoma and 88% for the model without considering de
novo carcinoma theory. The efficacy of diminutive adenoma and small adenoma increases with follow-up years, whereas the efficacy
of large adenoma decreases with follow-up years. In conclusion, about 30% of cancers arising from de novo sequence are
demonstrated. This finding, together with the adenoma–carcinoma sequence associated with adenoma size and histological type, is
important for the estimation of dwelling times, the efficacy of colonoscopy, and the surveillance of polyp after polypectomy.
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Although adenoma–carcinoma sequence was firmly established,
the disease natural history of colorectal neoplasm has been
challenged by the opposing theory of de novo carcinogenesis
(Kudo et al, 2000). The adenoma–carcinoma sequence theory, in
which cancer is thought to originate from the pre-existing
adenoma, has been generally accepted since Muto et al study
(1975). De novo carcinoma theory has been noted in several
Japanese studies since 1987 (Kudo et al, 2000) and further
confirmed in recent Western country studies (Bedenne et al, 1992;
Stolte and Bethke, 1995). The tenor of de novo carcinoma theory is
that many lesions of small colorectal early cancers of the
superficial type with nonpolypoid form (Kuramoto and Oohara,
1989; Shimoda et al, 1989), flat elevation or depressed type are
carcinomas without any adenomatous remnants (Kudo et al, 1995,
2000). Genetic studies also support the view that there are at least
two pathways that lead to the development of colonic cancer,
including polyp-cancer sequence and de novo (Hirota et al, 1995;
Tsujitani et al, 1996; Wada et al, 1996). While two opposing
theories were confirmed by histopathological studies, the relative
importance of the two theories associated with development of
colorectal carcinoma is still fraught with uncertainty. De novo
carcinoma accounting for development of colorectal carcinoma
ranges from 20 to 90%. To assess whether colorectal cancers are Revised 6 September 2002; accepted 27 March 2003
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lderived from adenoma–carcinoma sequence or de novo carcino-
ma, most studies retrospectively examined adenomatous remnants
on the basis of selected cancer cases rather than cases derived from
a longitudinal healthy cohort. In addition, few studies quantified
the progression rates pertaining to the development of colorectal
carcinoma following two theories. While a longitudinal follow-up
study requires long-term follow-up, it is therefore valuable to
elucidate the disease natural history of colorectal neoplasm taking
both pathways into account using an efficient cohort study design.
To shed light on the disease natural history associated with the two
theories, it is also important to assess the efficacy of endoscopy,
partly because transition parameters of the disease natural history
not only provide baseline estimates without being interrupted by
treatment and partly because early detection of flat- or depressed-
type cancer arising from de novo carcinoma is difficult with
endoscopy.
In addition to carcinogenesis of colorectal cancer, dwelling
times obtained from the disease natural history of progression
from adenoma to cancer by adenoma size and histological type
were not precisely estimated (Winawer et al, 1997). These findings
are very helpful for the evaluation of surveillance of polyp after
polypectomy, because tubular adenoma may have slow progres-
sion and too intensive follow-up for them after polypectomy seems
redundant. On the contrary, patients with the large adenomatous
polyp removed by polypectomy may need more intensive follow-
up. Arguably, since flat- or depressed-type cancer is difficult to be
detected with endoscopy, the proportion of de novo carcinoma
may also affect the efficacy of polypectomy. The aims of this study
are therefore
(1) to estimate the progression rate or dwelling time from normal,
through adenoma, and finally to invasive carcinoma, taking de
novo carcinoma into account;
(2) to estimate the progression rate or dwelling time from normal,
through adenoma, and finally to cancer by adenoma size and
histological type allowing for de novo carcinogenesis;
(3) to estimate the annual malignant transformation rate after
polypectomy by adenoma size and histological type;
(4) to assess the efficacy of colonoscopy in reducing colorectal
cancer, taking de novo carcinoma sequence into account,
based on the comparison of (1) or (2) with (3).
MATERIALS AND METHODS
Study design and data sources
There are two major parts involved in this study, including the
disease natural history, without being confounded by treatment
and malignant transformation after polypectomy. Study design
and data sources are individually described as follows.
The disease natural history of adenoma–carcinoma and de novo
carcinoma As pointed out earlier, there are two possible path-
ways accounting for the occurrence of invasive carcinoma of colon
and rectum. One of the pathways follows adenoma–carcinoma
sequence, that is, normal-adenoma-carcinoma. The other is
pertaining to the development of de novo cancers, like flat or
depressed cancers without adenomatous remnants. To estimate the
progression rates of adenoma–carcinoma sequence and direct
transition to de novo cancer, one needs data on the first
examination of colonoscopy because patients detected with
adenoma or invasive carcinoma in the first examination were
not confounded by treatment. This is illustrated in Figure 1 that
shows four hypothetical cases associated with the disease natural
history of adenoma–carcinoma and de novo carcinoma sequence
before first colonoscopic examination. Chronological orders from
birth (t0) to time window for the development of adenoma or
carcinoma before first examination are depicted by three time
points, including t1, t2, and t3. For simplicity, we assume that each
individual was normal at t1. Subject 1 remained free of adenoma
and invasive carcinoma before first examination. Subject 2 had
onset of adenoma at t2 and dwelled in the state of adenoma without
clinical symptoms until first examination. Subject 3 had depressed
nonpolypoid early colon cancer arising from de novo at t2 and
remained asymptomatic before first examination. Subject 4 had
onset of adenoma at t1 and progressed to early colon cancer
through adenoma–carcinoma sequence at t3, but remained
asymptomatic before first examination. The middle panel in
Figure 1 shows the observed detection modes of normal, adenoma,
invasive carcinoma arising from de novo, and invasive carcinoma
through adenoma–carcinoma sequence. The application of case–
cohort design and the Markov model (see below) enables one to
estimate the transition rates (average dwelling time, i.e. the inverse
of transition rate) of the disease natural history of the two
pathways. Taking de novo carcinoma sequence into account, the
three-state model is further extended to a five-state model by
dividing adenoma into three categories, diminutive (p5mm),
small (6–10mm), and large (410mm) according to Read et al
(1997) or by histological types (tubular (T), tubulovillous (TþV),
and villous (V)).
Data sources for estimating transition parameters were derived
from a total of 13908 subjects who underwent the first
examination of colonoscopy between 1979 and 1998 in Kaushouing
Medical center, the largest hospital in southern Taiwan. The reason
of selecting one medical center is to ensure that the quality of skill
did not vary greatly across colonoscopists. After receiving
colonoscopy, this cohort includes three groups, 10496 normal
subjects, 2652 polyps, and 760 CRC cases (excluding HNPCC and
FAP cases). Since the majority of subjects were examined between
1990 and 1998, the average follow-up years of this cohort excluding
760 cancers until the end of 1998 is 4.14 years, with 4.28 years for
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Figure 1 Clinical scenario of disease natural history model and
intervention model for colorectal neoplasm.
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lthe normal group and 3.58 years for patients with the initial
diagnosis as polyps. It should be noted that these 760 cancers
might consist of cancers arising from adenoma–carcinoma
sequence and de novo cancers. However, as some pathological
reports did not ascertain whether invasive tumours contain any
adenomatous remnants, we could not distinguish de novo cancers
from cancers from adenoma–carcinoma sequence. In addition,
since our pathological reports had not been computerised, instead
of collecting pathological findings for all adenoma we used an
efficient epidemiological design, a case–cohort design, to review
and collect a set of random samples. Given 90% power and 5%
statistical significant level, sample sizes using the ratio of approxi-
mately 1:2 for normal or adenoma vs cancer were calculated.
These include 305 normal subjects and 300 polyps that had not yet
progressed to invasive carcinoma until the end of 1998 were
randomly selected from normal and polyp cohorts, respectively. As
regards CRC, a total of 150 cancers were randomly selected. How-
ever, only 116 cases have complete information on pathological
finding. The overall process is diagrammed in Part I of Figure 2.
Demographic characteristics and endoscopy records for all
subjects who underwent colonoscopy were reviewed and collected.
Table 1 shows the distribution of gender and age by disease status.
The mean values of age are 49.57 (715.15) for normal subjects,
57.14 (713.60) for patients with polyps, and 60.56 (713.27) for
colorectal cancers. Sex ratios (male/female) are 0.93 for normal
subjects, 1.34 for patients with polyps, and 1.52 for colorectal
cancers. After selecting a subset of cohort, polyp size and
histological type were abstracted from medical charts and
pathological reports. Of 300 polyps, only 255 polyps had
information on polyp size (Table 2). Polyps include adenomatous
polyps and nonadenomatous polyps. Adenomatous polyps include
three types, tubular (T), tubulovillous (TþV), and villous (V)
(Read et al, 1997). Only 119 adenomatous polyps have information
on histological types and advanced colorectal cancers. As we used
a modelling method to estimate the proportions of de novo
carcinoma and adenoma–carcinoma sequence, we included all
colorectal invasive carcinoma including early and advanced
cancers as end point. All colorectal cancers in our study were
diagnosed according to the pathological findings in the light of
Duke’s stage classification. Early colorectal cancers are defined as
Duke’s stage A (limited to mucosa). Advanced cancer may include
B (into muscularis propria), C (regional nodal metastases), and D
(distant metastases).
Malignant transformation after polypectomy The bottom panel
of Figure 1 shows clinical scenario for the malignant transforma-
tion after polypectomy while adenomas were found. To ascertain
malignant transformation, all patients with polyps after poly-
pectomy in this cohort were linked to cancer registry data until the
end of 1998 (Part II of Figure 2). A total of 25 CRC cases were
ascertained with 35.71% diminutive adenoma, 28.57% small
adenoma, and 35.71% large adenoma in terms of adenoma size,
and 57.14% tubular adenoma, 28.57% tubulovillous adenoma, and
14.29% villous adenoma in terms of histological type. These cases
may be derived either from adenoma that overlooked in
colonoscopic examination, from recurrent adenoma depending
on adenoma size and histological type or de novo cancers that were
not diagnosed while colonoscopy was applied. These cases were
used to assess the effect of adenoma size and histological type on
the malignant transformation rate after polypectomy.
Statistical method
To elucidate the disease natural history of colorectal neoplasm for
both cancers arising from adenoma–carcinoma sequence and
cancers arising de novo (i.e. without any adenomatous compo-
nent), we proposed a three-state Markov model including the
progressions of adenoma–carcinoma sequence and de novo
carcinoma (see the middle panel of Figure 1).
Annual incidence rate of adenoma (l1) is defined as the force of
entering into adenoma per year. Annual transition rate from
adenoma to cancer (l2) is defined as the force of progression from
Part I  Part II 
Random sample 
Normal, N=10496 CRC, N=760  Polyp, N=2652 Follow-up by linking
cancer registry
25 CRC cases
Polypectomy 
Normal, N=305  CRC, N=116  Polyp, N=300
Malignant transformation
rate after polypectomy
Estimation of parameters associated
with disease natural history
Malignant
transformation
Figure 2 Study design and selection of samples for estimation of
parameters associated with disease natural history and follow-up of polyps
after polypectomy.
Table 1 Age, gender distribution, transition mode, and conditional transition probability by disease status of colorectal neoplasm from selected samples
Disease type Number of selected samples Age (mean7s.d.) Male/female subject Transition mode
Conditional
transition
probabilities
a
Normal 305 49.57715.15 0.93 Normal-Normal P1
*(t)
Polyp 300 57.14713.60 1.34 Normal-Polyp P2
*(t)
Invasive carcinoma 116 60.56713.27 1.52 Normal-Invasive carcinoma
b P3
*(t)
aFor the formula, see Appendix A;
bIncluding adenoma–carcinoma sequence and de novo carcinoma sequence.
Table 2 The frequencies of polyps by size and histological type
Clinical attributes Frequency Percentage (%)
Size groups
Diminutive polypsy (0.1–0.5cm) 204 80.0
Small polyps (0.6–1.0cm) 28 11.0
Large polyps (41.0cm) 23 9.0
Subtotal 255
Pathological type
Adenoma 119 64.3
Tubular 68 36.8
Tubulovillous 24 13.0
Villous 9 4.9
Adenoma (unclassified) 18 9.7
Nonadenomatous polyp 66 35.7
Subtotal 185
Disease progression of colorectal neoplasm and Markov model
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ladenoma to cancer per year. Annual incidence rate from normal to
de novo carcinoma (l3) is defined as the force of entering into de
novo carcinoma per year. Since only adenomas were modelled, we
assume that the disease is irreversible. The five-state Markov
models by adenoma size, normal-diminutive-small-large-
invasive carcinoma, and by histological types (normal-T-
TþV-V-invasive carcinoma) plus the pathway of direct
transition from normal to de novo carcinoma. There are two
rationales for using Markov models. First, since multistate
transitions rather than traditional two-state transition (normal-
disease) are involved, the Markov models are one of the
approaches for such a purpose. Second, the Markov model not
only deals with disease progression from different pathways, but
also accommodates unobservable transition like adenoma to
carcinoma due to the interruption of treatment. The detailed
algebra of three-state Markov models taking de novo carcinoma
into account is presented in Appendix A. Due to the Markov
property that assumes that the next transition is dependent on the
current transition but independent of the previous transition,
annual transition rate follows an exponential distribution. Conse-
quently, the inverse of annual transition rate gives an average
dwelling time staying in each state. The detailed methodology
related to the application of Markov model to the disease natural
history refers to Duffy et al (1995) and Chen et al (2000).
Estimation of parameters and the proportion of de novo carcinoma
are illustrated in Appendix A.
Estimation of parameters on malignant transformation after
polypectomy is based on accelerated failure time (AFT) model with
exponential distribution (Collett, 1994). To assess the efficacy of
polypectomy, one can calculate one minus the ratio of 5- or 10-
year probabilities of malignant transformation rate after poly-
pectomy (PT) to the corresponding transition probabilities
pertaining to the disease natural history (PN), see Appendix A
(Treatment efficacy¼1 PT/PN).
RESULTS
Descriptive results
Table 1 shows that adenoma and cancer are older than subjects
free of colorectal neoplasm. Patients with cancer are slightly older
than patients with adenoma. This suggests that the disease process
from normal, adenoma, and finally to invasive carcinoma is
progressive. Male subjects have more preponderance in adenoma
and cancer than females subjects. Table 2 shows the frequencies of
distribution by polyp size and histological type. Most polyps are of
diminutive polyps (size smaller than 5mm in diameter) and
tubular adenoma. There is a significant relation between size and
histological type (w
2¼14.81; P¼0.022) (data not shown). The
larger polyp is more likely to have villous structure than the
smaller one.
Natural history of adenoma–carcinoma of CRC
Table 3 shows the estimated results of three- and five-state natural
history models by adenoma size and histological types without
considering de novo carcinoma. For the three-state model, annual
incidence rate of adenoma is 3.1 10
 3. Annual transition rate
from adenoma to cancer is 2.2 10
 2. For the five-state model
depicted by adenoma size, annual transition rate from diminutive
to small adenoma is 3.8 10
 2. Annual transition rates from small
adenoma to large adenoma and from large adenoma to cancers are
1.3 10
 1 and 1.9 10
 1, respectively. The inverse of both these
figures gives 7.75 (1/0.1291) years and 5.27(1/0.1897) years of the
corresponding dwelling times.
For the five-state model associated with histological type, annual
transition rate from tubular to tubulovillous is 3.8 10
 2. Annual
transition rates from tubulovillous to villous and from villous to
cancers are 1.1 10
 1 and 2.8 10
 1, respectively. Similarly, the
estimates of dwelling time for tubulovillous type and villous type
are 9.46 (1/0.1057) years and 3.60 (1/0.2779) years, respectively.
Natural history of colorectal neoplasm taking de novo
cancer into account
Table 4 shows the estimated results by taking de novo cancer into
account. For the three-state model, annual incidence rate of
adenoma is 2.3 10
 3. Annual transition rate from adenoma to
cancer is 9.5 10
 3. Annual transition rate to de novo cancers is
7.3 10
 4. Using expression (A.5) (see Appendix A) yields 23.78%
of the proportion of de novo cancer. For the five-state model
associated with adenoma size, after considering de novo cancer,
annual incidence rate of adenoma is about 2.1 10
 3. Annual
transition rate from diminutive to small adenoma is 2.1 10
 2.
Annual transition rates from small to large adenoma and large
adenoma to invasive carcinoma are reduced to 5.7 10
 2 and
6.3 10
 2. The inverse of both these figures gives 17.48 and 15.90
years of the corresponding dwelling time. Annual transition rate to
de novo cancers is 9.5 10
 4. This gives 31.87% of cancers arising
from de novo sequence.
For the five-state model associated with histological type, annual
transition rate from normal to tubular adenoma is 2.2 10
 3.
Taking de novo cancer into account, annual transition rate from
tubular to tubulovillous adenoma is 2.3 10
 2. The annual
transition rates from tubulovillous to villous adenoma and villous
adenoma to invasive carcinoma are 5.1 10
 2 and 1.1 10
 1. The
inverse of both these figures gives 19.80 and 8.98 years of the
corresponding dwelling time. Annual transition rate to de novo
cancers is 8.6 10
-4. This gives 27.81% of cancers arising from de
novo sequence.
Transition rate after polypectomy of CRC
Of 2652 polyps, 25 cancers were ascertained with 3.58 average
years of follow-up. This gives 2.6 10
 3 (25/(9494¼2652 3.58))
of annual malignant transformation rate after polypectomy using
accelerated failure time model.
Compared to size less than 5mm, patients with adenoma size
between 6 and 10mm and larger than 1cm have 2.17-fold (0.58–
8.08) and 4.25-fold (1.23–14.70), respectively, for the risk of
malignant transformation (Table 5). The estimates of relative risk
for malignant transformation for tubulovillous and villous types
Table 3 Estimated results of natural history of adenoma–carcinoma of
colon and rectum by three Markov models
Transition mode Estimate 95% CI
Three-state model
Normal-adenoma 3.1 10
 3 2.6 10
 3–3.6 10
 3
Adenoma-invasive CRC 2.2 10
 2 1.6 10
 2–2.4 10
 2
Five-state model by adenoma size
Normal-diminutive adenoma 3.1 10
 3 2.6 10
 3–3.6 10
 3
Diminutive-small adenoma 3.8 10
 2 3.0 10
 2–4.7 10
 2
Small-large adenoma 1.3 10
 1 7.8 10
 2–1.8 10
 1
Large adenoma-invasive CRC 1.9 10
 1 9.5 10
 2–2.8 10
 1
Five-state model by histological type
Normal-tubular adenoma 3.1 10
 3 2.6 10
 3–3.6 10
 3
Tubular-tubulovillous
adenoma
3.8 10
 2 2.9 10
 2–4.7 10
 2
Tubulovillous-villous
adenoma
1.1 10
 1 6.5 10
 2–1.5 10
 1
Villous adenoma-invasive CRC 2.8 10
 1 1.0 10
 1–4.6 10
 1
Disease progression of colorectal neoplasm and Markov model
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lare 1.51 (95% CI: 0.45–5.01) and 2.53 (95% CI: 0.54–11.91)
compared to tubular adenoma.
Evaluation of efficacy for polypectomy
The ratio of annual malignant transformation rate after poly-
pectomy to the progression from adenoma to cancer in the light of
disease natural history in Table 3 without taking de novo cancers
into account gives 88% ((1 0.0026/0.022) 100%) as the efficacy
of polypectomy.
Taking adenoma size into account, Figure 3A shows the efficacy
of diminutive and small adenoma increases with follow-up years
and reaches full benefit around 10 and 20 years of follow-up,
whereas the efficacy of large adenoma decreases with follow-up
years. The efficacy of diminutive adenoma increases from 2.76% at
5 years to 63.54% at 10 years. The efficacy of large adenoma is
reduced from 91.47% at 5 years to 78.62% at 20 years. Similar
results are also found for the efficacy pertinent to histological type.
The efficacy for diminutive adenoma increases from 18.64% at 7
years to 48.03% at 10 years. The efficacy for villous adenoma is
reduced from 93.68% at 5-year to 80.94% at 20-year follow-up.
Taking de novo cancer into account, the efficacy of polypectomy is
reduced. The overall efficacy of polypectomy is reduced to 72.63%
((1 0.0026/0.0095) 100%) compared to 88%, without consider-
ing de novo cancer. The absolute efficacy in Figure 3B is smaller
than that in Figure 3A. However, the pattern of the efficacy of
polypectomy by adenoma size in Figure 3B is similar to that in
Figure 3A. The estimates of efficacy of polypectomy for large
adenoma are 80.64% after 5-year and 70.80% after 20-year follow-
up, taking de novo sequence into account. The estimates of efficacy
of polypectomy for villous adenoma are 88.31% after 5 years and
78.71% after 20 years, taking de novo sequence into account.
DISCUSSION
Colorectal neoplasm associated with the disease natural history,
the surveillance after polypectomy, and the efficacy of colono-
scopic examination were elucidated in this study. Using Markov
models, the first part quantified the disease natural history of
colorectal neoplasm from two pathways, the established adeno-
ma–carcinoma sequence and de novo cancers that have been
observed to arise in flat mucosa without adenomatous remnants.
Table 4 Estimated results of natural history of colorectal cancer, taking
de novo into account, by three Markov models
Transition mode Estimate 95% CI
Three-state model
Normal-adenoma 2.3 10
 3 1.3 10
 3–3.4 10
 3
Adenoma-invasive CRC 9.5 10
 3  5.5 10
 3–9.5 10
 3
Normal-CRC (de novo) 7.3 10
 4  2.4 10
 4–1.7 10
 3
Five-state model by adenoma size
Normal-diminutive adenoma 2.1 10
 3 1.4 10
 3–2.8 10
 3
Diminutive-small adenoma 2.1 10
 2 8.6 10
 3–3.3 10
 2
Small-large adenoma 5.7 10
 2 5.5 10
 3–1.1 10
 1
Large adenoma-invasive CRC 6.3 10
 2  2.9 10
 2–1.5 10
 1
Normal-CRC (de novo) 9.5 10
 4 3.6 10
 4–1.5 10
 3
Five-state model by histological type
Normal-tubular adenoma 2.2 10
 3 1.4 10
 3–3.0 10
 3
Tubular-tubulovillous
adenoma
2.3 10
 2 8.9 10
 3–3.7 10
 2
Tubulovillous -villous
adenoma
5.1 10
 2 1.0 10
 3–1.0 10
 1
Villous -invasive CRC 1.1 10
 1  4.14 10
 2–2.6 10
 1
Normal-CRC (de novo) 8.6 10
 4 1.9 10
 4–1.5 10
 3
Table 5 Estimates of parameters on malignant transformation by
adenoma size and histological type after polypectomy, using accelerated
failure time (AFT) model
Variable Hazard ratio 95% CI for hazard ratio
Size
0–0.5cm 1.00 –
0.6–1cm 2.17 0.58–8.08
41cm 4.25 1.23–14.70
Histological type
Tubular adenoma 1.00 –
Tubulovillous adenoma 1.51 0.45–5.01
Villous adenoma 2.53 0.54–11.91
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Figure 3 (A) Efficacy of reducing CRC with follow-up years by adenoma
size; (B) Efficacy of reducing CRC with follow-up years by adenoma size,
taking de novo into account.
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lAdenoma size and histological type were also taken into account
while the disease natural history of adenoma–carcinoma sequence
was modelled.
In addition to modelling the disease natural history of CRC
based on data from first colonoscopic examination, the second
part is related to the estimation of the overall annual malignant
transformation rate and the corresponding rates by adenoma size
and histological type after polypectomy.
The third part is to estimate the efficacy of colonoscopy in
reducing malignant transformation on the basis of parameters
from the first part of the disease natural history and the second
part of malignant transformation after polypectomy. Results from
the three parts can yield several significant implications for clinical
practice, including dwelling time of adenoma by size and
histological type, the proportion of cancers arising from de novo
cancers, the surveillance of adenoma after polypectomy, and the
efficacy of colonoscopy. These aspects associated with the disease
natural history model are discussed as follows.
Dwelling time of adenoma
The disease natural history model elucidated in this study can
throw light on the dwelling time of staying in precancerous lesion
by adenoma size and histological type. Without considering de
novo cancer sequence, the dwelling times are 26 years for
diminutive adenoma, 8 years for small adenoma, and 5 years for
large adenoma, respectively. The corresponding figures are 26
years for tubular adenoma, 9 years for tubulovillous adenoma, and
4 years for villous adenoma. Taking de novo cancer into account,
the dwelling times of adenoma are expected to be longer, with 48
years for diminutive adenoma, 17 years for small adenoma, and 16
years for large adenoma, respectively. The corresponding figures
are 44 years for tubular adenoma, 20 years for tubulovillous
adenoma, and 9 years for villous adenoma. The above estimates of
dwelling time of adenoma–carcinoma suggest a long window
period for early detection of adenoma using colonoscopy.
However, while de novo cancers are taken into account, the
dwelling times are longer. This suggests that detecting de novo
cancer by colonoscopy, possibly, with the spraying method cannot
be overemphasised. However, the efficacy of colonoscopy in
reducing cancers is highly dependent on the proportion of de novo
cancers (see below).
Adenoma–carcinoma or de novo cancer
Although two possible pathways, adenoma–carcinoma or de novo
cancer sequence, have been proposed, the relative importance of
both pathways to cancer has been rarely addressed. After taking
adenoma size or histological type into account, the present study
used five-state Markov models to identify around 30% cancers of
colon and rectum arising from de novo carcinoma. Using
transition parameters from the Markov model enables one to
predict the risk of getting de novo cancer. One-, 3-, 5-, 10-, and 20-
year probabilities from normal to de novo cancer were 0.15, 0.45,
1.5, and 2.9%, respectively, which are higher than the correspond-
ing figures 2.2 10
 5, 2.0 10
 4, 5.4 10
 4, 2.1 10
 3, and
7.8 10
 3 for cancer arising from adenoma–carcinoma sequence.
Surveillance of adenoma after polypectomy
The overall efficacy in reducing CRC with colonoscopy is 88%.
Taking de novo carcinoma into account, the efficacy is reduced to
73%. However, the efficacy of reducing CRC with polypectomy is
also contingent on size and histological type. The hazard ratios in
Table 5 show that large adenomatous polyps or villous adenoma
have a higher malignant transformation than diminutive, small, or
tubular adenoma. Taking these findings into account, there is a
decreasing linear relationship of the efficacy of polypectomy by
follow-up years for large adenomatous polyps but an increasing
trend with nonlinear relation for diminutive or small adenomatous
polyps (Figure 3A). Large adenomatous polyps have short dwelling
time leading to high potential of malignant transformation.
Consequently, the full efficacy is observed immediately after
polypectomy and decreases with follow-up years. In contrast,
dwelling times for diminutive and small adenoma are so long as to
be unlikely to yield benefit in short-term follow-up in comparison
with those without polypectomy. Full benefits are therefore
reached after 10 years of follow-up for small adenoma and 20
years of follow-up for diminutive adenoma. Similar findings are
also observed for histological type. The similar pattern, albeit the
efficacy is reduced, is observed while de novo carcinoma is
considered. The above findings suggest that the efficacy of
polypectomy is not only dependent on the proportion of cancers
arising from de novo carcinoma, but also varies according to
adenoma size and histological type.
Comparison with previous findings
Earlier studies on de novo carcinoma yielded varied results with
proportions of de novo cancers ranging from 20 to 90%. The
discrepancies across studies may be due to the difference between
the series in methods and in selection cases. Our finding of 30%
colorectal carcinoma arising from de novo carcinoma is slightly
lower than Bedenne et al’s (1992) result that was derived from a
nonselected population-based series of 1630 resected colorectal
cancer and much lower than the finding of 80–90% colorectal
carcinoma arising from de novo carcinoma sequence in Japanese
studies. Since our study was not based on evaluation of
adenomatous remnants of colorectal carcinoma, the misclassifica-
tion of de novo cancers such as flat-type into diminutive or small
adenoma due to being devoid of using the dye-spraying technique
in the present study provides an alternative explanation for lower
proportion of de novo carcinoma as compared with the Japanese
studies. This should be further corroborated in the ongoing study.
Nonetheless, our finding still suggests at least 30% colorectal
cancers arising from de novo carcinoma sequence.
If the disease natural history follows adenoma–carcinoma
theory, annual transition rate from adenoma to carcinoma is
2.20%, which is close to previous findings, including 1.99% in
Muto et al study (1975), 2.15% in NPS study (O’Brien et al, 1990),
and 2.15% in Stryker et al study (1987), respectively.
Annual malignant transformation rates by size and histological
type are also in agreement with previous findings that the
malignancy rate is higher in large adenomas and adenoma with
villous structure than in adenoma without exhibiting these features
(Muto et al, 1975; Wolff and Shinya, 1978). However, as discussed
in the previous part, the estimates of dwelling time will be reduced
if de novo carcinoma theory is considered. This suggests that
quantifying the disease natural history should take de novo
carcinoma into account.
Methodological consideration
In contrast to previous studies, the elucidation of the relative
importance of adenoma–carcinoma sequence and de novo cancer
was based on Markov models in our study (see Figure 1). The
optimal estimates associated with both pathways were therefore
obtained. The earlier studies on clarifying adenoma–carcinoma
sequence or de novo cancer were, retrospectively, to collect cancers
or flat cancer of colon and rectum and to ascertain de novo cancers
or adenoma–carcinoma sequence by examining whether there
were adenomatous remnants. However, the proportion of de novo
carcinoma is, in fact, dependent on what sort of cancer or how
large samples of cancers are collected. If flat cancers are more
likely to be included, the larger proportion of de novo cancer will
be obtained. This can account for why 80% flat cancers derived
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and only 22% in Stolte and Bethke study (1995). As cancers in the
present study were derived from a cohort receiving colonoscopy,
they were composed of cancers from two pathways. Consequently,
the estimate of 30% would have represented the proportion of
subjects as the same cohort in the present study with the potential
of the development of de novo cancer if they had chance of
developing into cancer.
There are two limitations in this study. First, to uncover invasive
carcinoma by linking all polyps with cancer registry may not only
consist of missed polyps but also include new polyps, recurrent
polyps, and possible de novo carcinoma that coexist with polyp
and those undetected in colonoscopy examination. The efficacy of
polypectomy in the current study may be related not only to
lesions overlooked in colonoscopy examination but also recurrent
polyps, new polyps, and de novo cancer. However, although our
models can take de novo into account, they still have limitations in
separating recurrent polyps or new polyps from missed polyps.
Second, we used information of age of diagnosis at first
examination and different modes (normal, adenoma, and cancer),
together with the technique of Markov model to yield the estimates
of the disease natural history model including adenoma–
carcinoma and de novo carcinoma. However, the Markov property
needs to assume constant transition rates. This assumption, of
course, may not be valid for cancer incidence but may be
reasonable for adenoma for subjects aged over 50 years because
they had already had adenoma before first examination. As the
majority of subjects receiving colonoscopy in this cohort were
older than 50 years, we believe the assumption may not be
unreasonable. This can be supported by a good fit between the
observed and the expected for the five-state Markov model-
associated adenoma size (w
2¼0.15, P¼0.70).
In conclusion, the disease natural history of adenoma–
carcinoma by adenoma size and histological type and de novo
carcinoma sequence was quantified using Markov models. About
30% of cancers were estimated to arise from de novo sequence.
Considerations of de novo carcinoma and adenoma–carcinoma
sequence associated with adenoma size and histological type play
an important role in the estimation of dwelling times, the efficacy
of colonoscopy, and the surveillance of polyp after polytectomy.
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Appendix A. Derivation of transition matrix, transition probabilities, and the likelihood function of three-state Markov model for
the disease natural history of colorectal neoplasm
Transition matrix
The three-state model for the disease natural history of colorectal
neoplasm taking de novo carcinoma into account (Figure 1) is
Normal
(State 1)
Adenoma
(State 2)
Invasive CRC
(State 3)
3 (De novo carcinoma)
1 2
→→
The definition of l1, l2, and l3 refers to the methodological
section. The transition parameters of l1, l2, and l3 can be written
in a transition matrix form (Q):
Currentstate
12 3
Q ¼ Previousstate
1
2
3
 ðl1 þ l3Þ l1 l3
0  l2 l2
00 0
0
@
1
A
ðA:1Þ
Derivation of transition probabilities
Following Duffy et al (1995) and Chen et al (2000), transition
probabilities for the transition from one state to another are
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Currentstate
12 3
P ¼ Previousstate
1
2
3
P11ðtÞ P12ðtÞ P13ðtÞ
0 P22ðtÞ P23ðtÞ
00 P33ðtÞ
0
@
1
A
ðA:2Þ
Pij(t) represents the risk of transition from state i to state j. For
example, the risk of transition from normal to invasive CRC during
time t is denoted by P13(t).
Likelihood and estimation of parameter
As our study is based on a case–cohort design, the conditional
probability for polyp (state 2) given whether the sample was
selected (S¼1) is required and denoted as follows:
P 
2ðtÞ¼PrðState2atfirstexaminationatagetjwhethertobesampledÞ
¼ PrðP12ðtÞjS ¼ 1Þ
¼
PrðS ¼ 1jP12ðtÞÞ P12ðtÞ
P3
j¼1 PrðS ¼ 1jP1jðtÞÞ P1jðtÞ
¼
p2 P12ðtÞ
P3
j¼1 pj P1jðtÞ
ðA:3Þ
p1 (¼305/10496), p2 (¼300/2652), and p3 (¼116/760) are
random sample fractions for normal, polyp, and invasive
carcinoma, respectively.
Similar formulae are derived for normal (P1
*(t)) and invasive
carcinoma (P3
*(t)). Given these probabilities, one can develop the
likelihood function based on the frequency in Table 1. Let n1
(¼305), n2 (¼300), and n3 (¼116) denote the number of normal,
polyp, and invasive CRC, respectively. The likelihood function,
given this information, is
Y 3
j¼1
Y nj
i¼1
P 
j ðmiÞ
dij ðA:4Þ
where mi represents age at first examination of the ith indivi-
dual and dij is an indicator for the ith individual in state
j (j¼1, 2 , 3).
SAS/IML procedure was used to estimate maximum likelihood
estimates (MLEs) and standard error of estimates in Tables 3
and 4.
Calculation of de novo carcinoma (P)
Using transition parameters of l1 and l3, it is easy to show that the
proportion of de novo carcinoma (P) is calculated by
P ¼
l3
l1 þ l3
ðA:5Þ
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